Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154), and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
Research Square (Research Square)